Evidence map›Paper›PMID 40237823›Full record

ArticleBiotechnology letters2025

Construction and immunogenicity analysis of a recombinant baculovirus targeting the N protein of SARS-CoV-2.

Bohan Yu, Xiaoli Mo, Li Sui, Yujia Fang, Xudong Tang, Ping Qian

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bohan YuJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China.
Xiaoli MoJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China.
Li SuiJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China.
Yujia FangJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China.
Xudong TangJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China.
Ping QianJiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang, 212100, China. qianping@just.edu.cn.ORCID http://orcid.org/0000-0003-3613-7167

Funding

Open Project of Key Laboratory of Silkworm and Mulberry Genetic Improvement KL202204Open Project of Key Laboratory of Silkworm and Mulberry Genetic Improvement KL202205the Postgraduate Research & Practice Innovation Program of Jiangsu Province SJCX24_2580Zhenjiang Agricultural Technology Support Project NY2023004
6 · The paper itself

Abstract

objectivesThis study aimed to construct recombinant baculoviruses capable of expressing the nucleocapsid N protein of SARS-CoV-2 and to assess the effects of co-administration with sodium butyrate on its expression and immunogenicity.

resultsThe recombinant BmNPV expressed green fluorescent protein in BmN cells and N protein in mammalian cells. The addition of sodium butyrate significantly enhanced the expression of N protein in HEK293T cells. Following intramuscular injection of recombinant BmNPV into mice, specific antibodies against the N protein were detectedon day 7, 21, and 35. Co-administration with sodium butyrate (1000 mg/kg body weight) significantly enhanced the immunogenicity of the recombinant virus.

conclusionsRecombinant BmNPV expressing the SARS-CoV2 N protein successfully inducedthe anti-N immunogenicity in mice, providing a solid foundationfor the development of novel subunit vaccines against SARS-CoV-2.

Indexed as

BaculoviridaeCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 VaccinesPhosphoproteinsSARS-CoV-2AnimalsAntibodies, ViralFemaleGreen Fluorescent ProteinsHEK293 CellsHumansMiceMice, Inbred BALB CRecombinant ProteinsAntibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19 VaccinesGreen Fluorescent Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsRecombinant ProteinsBaculovirusCOVID-19 N proteinImmunogenicity protein expressionSodium butyrate

Identifiers

PMID40237823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.